drugset / Trial / NCT01744379

Single and Multiple Dose Study in Japanese

NCT01744379

Phase 1 Completed 40 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will explore the safety, tolerability, and serum uric acid lowering effect of lesinurad in healthy Japanese males to allow comparison with the Western population.

Timeline

Start
2012-12
Primary completion
2013-03
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lesinurad Small molecule 50 mg
Subject Lesinurad Small molecule 100 mg
Subject Lesinurad Small molecule 200 mg
Subject Lesinurad Small molecule 400 mg
Subject Lesinurad Small molecule 600 mg

Indications